InspireMD Inc. (NSPR): Price and Financial Metrics
NSPR Price/Volume Stats
| Current price | $2.09 | 52-week high | $3.85 |
| Prev. close | $2.14 | 52-week low | $0.96 |
| Day low | $2.07 | Volume | 15,800 |
| Day high | $2.15 | Avg. volume | 34,982 |
| 50-day MA | $2.45 | Dividend yield | N/A |
| 200-day MA | $2.88 | Market Cap | 49.03M |
NSPR Stock Price Chart Interactive Chart >
InspireMD Inc. (NSPR) Company Bio
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. is headquartered in Tel Aviv, Israel.
Latest NSPR News From Around the Web
Below are the latest news stories about INSPIREMD INC that investors may wish to consider to help them evaluate NSPR as an investment opportunity.
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection SystemReflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of strokeTEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No. 11,844,893, titled, “Shunts with Blood Flow Indicators.” |
InspireMD's Gary Roubin Acquires 13% More StockInvestors who take an interest in InspireMD, Inc. ( NASDAQ:NSPR ) should definitely note that insider Gary Roubin... |
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem LesionsStudy to enroll 15 acute stroke patients across three U.S. sitesTEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the company has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo, and Dr. Adnan Siddiqui, Vice-Chairman and Professor of Neurosurgery, to execute an Early Feasibility St |
InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call TranscriptInspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript November 6, 2023 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.17. Operator: Good morning. And welcome to the InspireMD Third Quarter of 2023 Earnings Call. Currently, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. […] |
InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ...Positive 30-day results from C-GUARDIANS U.S. IDE clinical trial and CMS' decision to expand CAS coverage contribute to the company's growth |
NSPR Price Returns
| 1-mo | -9.91% |
| 3-mo | -32.58% |
| 6-mo | -36.67% |
| 1-year | 114.32% |
| 3-year | -68.70% |
| 5-year | -96.80% |
| YTD | -25.62% |
| 2023 | 226.93% |
| 2022 | -71.54% |
| 2021 | -40.94% |
| 2020 | -68.44% |
| 2019 | -86.42% |
Loading social stream, please wait...